Back to Clinical Trials

Clinical Trials: Medical Oncology


Source: Italfarmaco
In this phase III, multicenter study, 1200 patients with lung, breast, gastrointestinal (stomach, colon-rectum, pancreas), ovarian or head and neck cancer undergoing chemotherapy will be randomly assigned (at the beginning of cytotoxic therapy) in a 2:1 ratio and in double-blind conditions to a treatment with subcutaneous low molecular weight heparin (nadroparin calcium, one injection/day) or placebo for the overall duration of chemotherapy or up to a ... Read More
Last Updated: 30 Jan 2012
Source: University of Giessen
The trial will test the effectiveness and toxicity of subcutaneous treatment with one cycle of cladribine in patients with hairy cell leukemia requiring treatment. They have to be untreated so far or may be pretreated with alpha-interferon. Read More
Last Updated: 24 Oct 2016
Source: University of Giessen
The study will test the effectiveness (rate of complete remissions, total remission rate and duration of remission) and toxicity of the combined immuno/chemotherapy with subcutaneous cladribine (LITAK®) plus anti-CD20* antibody rituximab in patients requiring treatment for relapsed hairy cell leukaemia or hairy cell leukaemia variant independent of any previous therapy. CD20* = cluster of differentiation antigen 20 Read More
Last Updated: 02 Jun 2014
Source: Dendreon
The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGE®) therapy, and to follow all subjects for survival. Read More
Last Updated: 05 Jun 2016
Source: Celgene Corporation
The purpose of the Connect® MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) and provide unique insights into the management of MM and the impact of this hematologic disorder on patients. Read More
Last Updated: 07 Jul 2016
Source: Telik
The purpose of this study is to determine if TLK286(Telcyta) is more effective than gefitinib (Iressa) in the treatment of non-small cell lung cancer. Read More
Last Updated: 09 Jan 2008
Source: Millennium Pharmaceuticals, Inc.
This is a randomized, open label, multicenter clinical trial to compare the efficacy and safety of Velcade (bortezomib) and dexamethasone versus Velcade, thalidomide, and dexamethasone versus Velcade, melphalan, and prednisone in patients with previously untreated multiple myeloma not considered candidates for high-dose chemotherapy and autologous stem cell transplantation. Read More
Last Updated: 27 Mar 2014
Source: Hellenic Cooperative Oncology Group
The purpose of this study is to determine whether cabazitaxel is effective in the treatment of metastatic breast cancer. Read More
Last Updated: 05 Oct 2016
Source: Telik
The purpose of this research study is to determine if TLK286 given in combination with carboplatin is more effective than liposomal doxorubicin in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer, that is refractory or resistant to platinum chemotherapy. Read More
Last Updated: 29 May 2012
Source: Chiron Corporation
The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with low-grade Non-Hodgkin's Lymphoma who have previously failed Rituxan treatments. Read More
Last Updated: 01 Feb 2006
Source: Bristol-Myers Squibb
The purpose of this study is to estimate the incidence and characterize the outcome of high grade, select adverse events in subjects with advanced or metastatic NSCLC treated with Nivolumab. Read More
Last Updated: 22 Jan 2017
Source: SCRI Development Innovations, LLC
This is a randomized, Phase III, open-label, multicenter study. Read More
Last Updated: 31 May 2016
Source: Telik
The purpose of this study is to demonstrate superiority in survival in favor of TLK286 as compared to active control therapy with Doxil/Caelyx or Hycamtin in the intent-to-treat (ITT) populations. Read More
Last Updated: 20 Jul 2011
Source: Southwest Oncology Group
The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon cancer. Read More
Last Updated: 11 Oct 2016
Source: Helsinn Healthcare SA
PALO-15-17 is a clinical study assessing efficacy and safety of a single dose of palonosetron 0.25 mg administered as a 30-minute IV infusion compared to palonosetron 0.25 mg administered as a 30-second IV bolus (Aloxi, an antiemetic drug), both given with oral dexamethasone. The objective of the study is to demonstrate that infused IV palonosetron 0.25 mg is as effective as (non-inferior to) injected palonosetron IV 0.25 mg to prevent nausea and vomiting ... Read More
Last Updated: 11 May 2016
Source: Novartis
This trial will evaluate two separate groups of patients with stage IIIB/IV non-small cell lung cancer. The objective of Group 1 is to investigate an FDA-approved drug in stage IIIB/IV non-small cell lung cancer patients that has spread to the bones. The objective of Group 2 is to see if a blood test can be used to predict when cancer-related bone lesions develop. This trial is seeking patients 18 years or older that have been diagnosed with Stage IIIB or ... Read More
Last Updated: 19 Nov 2009
Source: Eisai Inc.
This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for their lung cancer. Read More
Last Updated: 06 Jul 2012
Source: Mast Therapeutics, Inc.
The objective of this trial is to compare efficacy and safety of CoFactor and 5-fluorouracil (5-FU) versus leucovorin and 5-FU in treatment of metastatic colorectal cancer. Read More
Last Updated: 21 Aug 2008
Source: Bristol-Myers Squibb
The purpose of this study is to better understand the use of tyrosine kinase inhibitors (TKI) in patients newly diagnosed with CML and their quality of life in a real-world setting. Read More
Last Updated: 17 Mar 2016
Source: Telik
The purpose of this trial is to study the efficacy and safety of the triplet combination of TLK286, carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer. Read More
Last Updated: 29 May 2012
Page 1 of 50